The Business and the Science Behind 23andMe: Chronic Kidney Disease

Authors

Kaitlyn Smith, Ursinus CollegeFollow
Brianna Valerio, Ursinus CollegeFollow
Abigail Schwerdt, Ursinus CollegeFollow
Prakash Sembhi, Ursinus CollegeFollow
Jessica Rogers, Ursinus CollegeFollow
Colin Holtzman, Ursinus CollegeFollow
Kevin Devlin, Ursinus CollegeFollow
Samantha Aguirre, Ursinus CollegeFollow
Braden Burns, Ursinus CollegeFollow

Document Type

Paper

Publication Date

4-22-2021

Faculty Mentor

Rebecca Roberts and Steven Aukers

Abstract

23andMe is a new and emerging company for the general public to inquire about both their ancestry and potential health risks. The field of genetic testing has become increasingly more popular over the past few years with a high demand market that can vary by region and a variety of demographics. Chronic kidney disease (CKD) is characterized by kidney damage so extensive that the kidneys can no longer properly function to filter waste and excess fluid from the body. 23andMe can test a customer's risk of developing CKD by examining if they are at high risk for PKD1 and APOL1 protein mutations. 23andMe produces high clinical and analytical reproducibility with 5 confidence intervals to choose from. This market has opened doors in both the public and private sectors to unite some of the brightest minds in research.

Comments

Presented as part of the Ursinus College Celebration of Student Achievement (CoSA) held April 22, 2021.

The downloadable .mp4 video file is a poster presentation with audio commentary with a run time of 15:35.

Attached as a supplemental file Is a poster summarizing our findings.

Recommended Citation

Smith, Kaitlyn; Valerio, Brianna; Schwerdt, Abigail; Sembhi, Prakash; Rogers, Jessica; Holtzman, Colin; Devlin, Kevin; Aguirre, Samantha; and Burns, Braden, "The Business and the Science Behind 23andMe: Chronic Kidney Disease" (2021). Biology Presentations. 26.
https://digitalcommons.ursinus.edu/biology_pres/26